61 related articles for article (PubMed ID: 28928088)
1. 20(S)-Ginsenoside Rh2 suppresses proliferation and migration of hepatocellular carcinoma cells by targeting EZH2 to regulate CDKN2A-2B gene cluster transcription.
Li Q; Li B; Dong C; Wang Y; Li Q
Eur J Pharmacol; 2017 Nov; 815():173-180. PubMed ID: 28928088
[TBL] [Abstract][Full Text] [Related]
2. Combination of curcumin with N-n-butyl haloperidol iodide inhibits hepatocellular carcinoma malignant proliferation by downregulating enhancer of zeste homolog 2 (EZH2) - lncRNA H19 to silence Wnt/β-catenin signaling.
Khan H; Ni Z; Feng H; Xing Y; Wu X; Huang D; Chen L; Niu Y; Shi G
Phytomedicine; 2021 Oct; 91():153706. PubMed ID: 34517264
[TBL] [Abstract][Full Text] [Related]
3. 20(S)-Ginsenoside Rh2 inhibits hepatocellular carcinoma by suppressing angiogenesis and the GPC3-mediated Wnt/β‑catenin signaling pathway.
Xu L; Li J; Hou N; Han F; Sun X; Li Q
Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(5):688-696. PubMed ID: 38584523
[TBL] [Abstract][Full Text] [Related]
4. Targeting WNT/β-Catenin via Modulating EZH2 Function: A New Chapter in the Treatment of β-Catenin Mutant Hepatocellular Carcinoma?
Hung MH; Wang XW
Cancer Res; 2023 Nov; 83(21):3498-3500. PubMed ID: 37747420
[TBL] [Abstract][Full Text] [Related]
5. Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma.
Csepregi A; Ebert MP; Röcken C; Schneider-Stock R; Hoffmann J; Schulz HU; Roessner A; Malfertheiner P
BMC Cancer; 2010 Jun; 10():317. PubMed ID: 20569442
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target.
Cao J; Pontes KC; Heijkants RC; Brouwer NJ; Groenewoud A; Jordanova ES; Marinkovic M; van Duinen S; Teunisse AF; Verdijk RM; Snaar-Jagalska E; Jochemsen AG; Jager MJ
J Pathol; 2018 Aug; 245(4):433-444. PubMed ID: 29732557
[TBL] [Abstract][Full Text] [Related]
7. Interplay of DNA methyltransferase 1 and EZH2 through inactivation of Stat3 contributes to β-elemene-inhibited growth of nasopharyngeal carcinoma cells.
Wu J; Tang Q; Yang L; Chen Y; Zheng F; Hann SS
Sci Rep; 2017 Mar; 7(1):509. PubMed ID: 28360411
[TBL] [Abstract][Full Text] [Related]
8. Methyltransferase Inhibition Enables Tgf
Liu YT; Romero C; Xiao X; Guo L; Zhou X; Applebaum MA; Xu L; Skapek SX
Mol Cell Biol; 2023; 43(3):115-129. PubMed ID: 36941772
[No Abstract] [Full Text] [Related]
9. Cyclin-Dependent Kinase Inhibitor 2b Controls Fibrosis and Functional Changes in Ischemia-Induced Heart Failure via the BMI1-p15-Rb Signalling Pathway.
Yang W; Zhang A; Han Y; Su X; Chen Y; Zhao W; Yang K; Jin W
Can J Cardiol; 2021 Apr; 37(4):655-664. PubMed ID: 32428618
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of VHL-based EZH2 degraders for breast cancer.
Xiao B; Shi Z; Liu J; Huang Q; Shu K; Liu F; Zhi C; Zhang D; Wu L; Yang S; Zeng X; Fan T; Liu Z; Jiang Y
Bioorg Chem; 2024 Feb; 143():107078. PubMed ID: 38181661
[TBL] [Abstract][Full Text] [Related]
11. Ginsenoside Rh2 and its octyl ester derivative inhibited invasion and metastasis of hepatocellular carcinoma via the c-Jun/COX2/PGE2 pathway.
Hu QR; Huang QX; Hong H; Pan Y; Luo T; Li J; Deng ZY; Chen F
Phytomedicine; 2023 Dec; 121():155131. PubMed ID: 37806155
[TBL] [Abstract][Full Text] [Related]
12. Anti-proliferative activities of sinigrin on carcinogen-induced hepatotoxicity in rats.
Jie M; Cheung WM; Yu V; Zhou Y; Tong PH; Ho JW
PLoS One; 2014; 9(10):e110145. PubMed ID: 25329483
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic Control of
Koss B; Shields BD; Taylor EM; Storey AJ; Byrum SD; Gies AJ; Washam CL; Choudhury SR; Hyun Ahn J; Uryu H; Williams JB; Krager KJ; Chiang TC; Mackintosh SG; Edmondson RD; Aykin-Burns N; Gajewski TF; Wang GG; Tackett AJ
Cancer Res; 2020 Nov; 80(21):4707-4719. PubMed ID: 33004350
[TBL] [Abstract][Full Text] [Related]
14. EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2.
Lai Y; Han X; Xie B; Xu Y; Yang Z; Wang D; Li W; Xie Y; Song W; Zhang X; Xia JQ; Zhang P
Cancer Sci; 2024 Apr; ():. PubMed ID: 38623968
[TBL] [Abstract][Full Text] [Related]
15. Ginsenoside Rh2 inhibits invasiveness of glioblastoma through modulation of VEGF-A.
Li S; Gao Y; Ma W; Cheng T; Liu Y
Tumour Biol; 2015 Jul; ():. PubMed ID: 26219892
[TBL] [Abstract][Full Text] [Related]
16. Cyclohexene oxide CA, a derivative of zeylenone, exhibits anti-cancer activity in glioblastoma by inducing G0/G1 phase arrest through interference with EZH2.
Su R; Cao W; Ma G; Li W; Li Z; Liu Y; Chen L; Chen Z; Li X; Cui P; Huang G
Front Pharmacol; 2023; 14():1326245. PubMed ID: 38264522
[No Abstract] [Full Text] [Related]
17. Making liver cancer cells go ARGh!
Henneberg AL; Opitz CA
EMBO J; 2022 Nov; 41(21):e112415. PubMed ID: 36222348
[TBL] [Abstract][Full Text] [Related]
18. ACTR5 controls CDKN2A and tumor progression in an INO80-independent manner.
Xu X; Chan AKN; Li M; Liu Q; Mattson N; Pangeni Pokharel S; Chang WH; Yuan YC; Wang J; Moore RE; Pirrotte P; Wu J; Su R; Müschen M; Rosen ST; Chen J; Yang L; Chen CW
Sci Adv; 2022 Dec; 8(51):eadc8911. PubMed ID: 36563143
[TBL] [Abstract][Full Text] [Related]
19. Mechanism Research and Application for Ginsenosides in the Treatment of Hepatocellular Carcinoma.
Zhou N; Mao F; Cheng S
Biomed Res Int; 2023; 2023():7214037. PubMed ID: 38027042
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
